Joseph Grogan was most recently the director of the United States Domestic Policy Council and assistant to President Donald Trump. Appointed by Acting Chief of Staff Mick Mulvaney, Grogan converted the traditionally small office into an influential policy council.
Grogan worked from 2017 to January 2019 as a health care official in the Office of Management and Budget. He was appointed a member of the White House Coronavirus Task Force in January 2020.
He currently serves on the board of directors of Verde Technologies.
Michael Abramoff, MD, PhD
Founder and Executive Chairman
Dr. Michael D. Abramoff, MD, PhD, is a fellowship-trained retina specialist, computer scientist and entrepreneur. He is Founder and Executive Chairman of Digital Diagnostics, the first company ever to receive FDA clearance for an autonomous AI diagnostic system. To transform the quality, accessibility, and affordability of global healthcare through the automation of medical diagnosis and treatment.
Dr. Michael Abramoff, MD, PhD, (FARVO) is the Robert C. Watzke, MD Professor of Ophthalmology and Visual Sciences at the University of Iowa, with a joint appointment in the College of Engineering. Dr. Abramoff is the Founder and Executive Chairman of Digital Diagnostics, the Autonomous AI diagnostics company that was the first in any field of medicine to get FDA clearance for an autonomous AI.
In primary care, it can instantaneously diagnose diabetic retinopathy and diabetic macular edema at the point of care. Dr Abramoff developed an ethical foundation for autonomous AI that was used during the design and validation, and regulatory and payment pathways for autonomous AI.
As the author of over 300 peer-reviewed publications in this field, he has been cited over 31,000 times, and is the inventor on 17 issued patents and many patent applications. Dr. Abramoff has mentored dozens of engineering graduate students, ophthalmology residents, and retina fellows.
His passion is to use AI to improve the affordability, accessibility and quality of care.
Chief Executive Officer
John Bertrand brings over a decade of healthcare technology experience to Digital Diagnostics, previously holding a variety of executive roles at Epic Systems. During his 12-year career with Epic, Bertrand led cross-functional teams in a variety of product, customer success, and business development roles with a focus on growth.
Most recently Bertrand served as Executive in Residence at 8VC, a leading Silicon Valley venture capital firm focused on healthcare technology. His time in this space focused on the application of artificial intelligence and computer vision in healthcare.
President and COO
Seth Rainford is the President and COO at Digital Diagnostics where he focuses on expanding market opportunities and driving operational excellence within the company.
Rainford brings more than a decade of executive experience to Digital Diagnostics including the successful management of large-scale P&L’s, strong organic & inorganic business development expertise, as well as complex multi-site operations leadership within the healthcare industry.
Rainford most recently served as Regional Vice President & General Manager of LabCorp in the Greater Chicago Area, leading a strategic transformation of the Midwest business unit. Previously, he served as Vice President at Northwestern Medicine, where he drove the commercialization and scaling of their outreach diagnostics business.
Rainford received his MBA in business administration from Purdue University.
Meindert Niemeijer, PhD
CTO & SVP of Research and Development
Dr. Niemeijer has been with Digital Diagnostics since 2011. He is an internationally recognized medical image analysis expert with more than 15 years of experience researching and developing machine learning software and algorithms for the analysis of medical images.
He received his PhD in medical image analysis and machine learning at Utrecht University in the Netherlands in 2006. Dr. Niemeijer has published more than 50 papers, a book chapter and holds several medical imaging patents.
As Digital Diagnostics CTO, he is responsible for managing the engineering, IT and R&D departments. Previously Dr. Niemeijer worked as a senior scientist at Philips Research and as a researcher at Utrecht University Medical Center and the University of Iowa.
Michael Vigoda, MD
Chief Clinical Officer
As Chief Clinical Officer, Michael Vigoda translates our technology platform’s value proposition for our provider customers addressing workflow considerations and clinician perspectives that would impact adoption/usage of our products.
Michael brings several decades of clinical, administrative and informatics experience at nationally recognized academic medical centers. Most recently, he was an independent EHR consultant after serving as Chief Medical Information Officer of Bon Secours Health System.
Michael has a Masters in Computer Science and MD from UW-Madison, MBA from Kennesaw State. He is board certified in Anesthesia and practiced pediatric anesthesia for over 20 years, following residencies in Pediatric and Anesthesia, Pediatric Anesthesia fellowship and a one year clinical Neonatology fellowship.
Chief of Staff
As Chief of Staff, Danika Simonson provides support and strategic guidance to the executive team at Digital Diagnostics.
She has held a variety of leadership roles in account management, customer success and marketing at Digital Diagnostics and Dyson. She has a B.S. in Applied Mathematics from Columbia University.
Ryan Amelon, PhD
Vice President of Product
Dr. Ryan Amelon joined Digital Diagnostics in 2013 where he was quickly promoted to R&D Director, a position he held for several years before being promoted to VP of Product in 2019.
As R&D Director Dr. Amelon played an instrumental role in developing the company’s flagship product IDx-DR, a system that automatically detects diabetic retinopathy in retinal images. Dr. Amelon was central in the development and validation of the IDx-DR AI components that facilitated the landmark FDA clearance. As VP of Product Dr. Amelon is responsible for managing the product team that establishes the direction and execution for all things IDx-DR.
Dr. Amelon graduated with a PhD in Biomedical Engineering from the University of Iowa in 2012. Dr. Amelon enjoys finding novel applications for automated diagnosis both through applications within the eye and beyond.
Vice President of International Sales
Dana Cooney joined Digital Diagnostics as the VP of International Sales where she is responsible for the development and implementation of company strategy and the commercialization of sales outside the U.S.
Dana brings an extensive sales background to her position at Digital Diagnostics, most recently as Sales Director for CIVCO Medical Solutions, where she developed and executed sales and marketing strategies to consistently deliver profitable sales growth, market share gains, and the attainment of all financial objectives in Asia-Pacific and Canada.
Dana received her Master’s in Business Administration from the University of Iowa. A native Iowan, Dana still lives in the Iowa City area.
Vice President of Dermatology
Liz is the former CEO and Co-Founder of 3Derm, a skin cancer diagnostics company based on her undergraduate research at Yale University that was acquired by Digital Diagnostics in 2020. 3Derm developed skin imaging systems and machine learning algorithms to triage patients’ skin concerns. Her team conducted three clinical studies and became the first company to obtain FDA Breakthrough Status for their skin cancer algorithms. Through their commercialized teledermatology platform, 3Derm now serves thousands of patients at health systems in the US. Liz has raised several rounds of capital, attracted over a million dollars in public and private research grants, and led the efforts to secure teledermatology coverage from several major payers. She is actively involved with local and national health tech policy groups testifying and drafting legislation advocating for telemedicine reimbursement. Liz holds a bachelor’s degree in Biomedical Engineering.
Elliot is the former CTO and Co-Founder of 3Derm, a skin cancer diagnostics company based on his undergraduate research at Yale University, which was acquired by Digital Diagnostics in 2020. 3Derm developed skin imaging systems and machine learning algorithms to triage patients’ skin concerns.
Through their commercialized teledermatology platform, 3Derm now serves thousands of patients at health systems in the US. Elliot architected and managed the development of their scalable, high security platform for the transmission and triage of dermatology cases, as well as their specialized camera systems. He also led 3Derm’s AI and data science efforts.
Prior to 3Derm, Elliot’s research background includes gene therapy work at the Khavari Dermatology Lab and biologically inspired machine-learning research in the STAIR Lab, both at Stanford University. He also conducted research at Johns Hopkins’ Thakor Lab studying methods to make smart prosthetics more reliable and easier to use. Elliot Swart studied computer science and electrical engineering at Yale University.
Vice President of Operations
As VP of Operations, Sarah Tibesar is responsible for strategy and execution across the Customer Experience, Human Resources, and Administration areas of Digital Diagnostics.
Sarah brings more than a decade of experience leading high-caliber customer success and implementation teams in rapid-growth environments, with specialization in the healthcare and customer experience industries. Most recently, Sarah served as Director of Professional Services for Zendesk, where she scaled the North American practice through ongoing operational enhancements and built a thriving practice in Latin America from the ground up.
Sarah earned her MBA and BS in Mechanical Engineering from Washington University in St. Louis.
Todd Rahmes has over 25 years’ experience as an attorney representing emerging growth companies including in a nationally recognized law firm, as inhouse counsel for a semiconductor company, and as General Counsel of Infinity Financial Technology. While at Infinity Todd shepherded the company through an IPO and a subsequent acquisition by Sungard Data Systems, after which he became General Counsel for seven Fintech companies under the Sungard umbrella.
At Infinity and Sungard, as part of his GC role, he negotiated large, key enterprise software transactions with tier 1 banks worldwide, negotiated with strategic partners both in the acquisition of technology as well as the expansion of markets. He worked closely with sales, executive, and engineering teams.
Most recently, Todd was a partner in a technology law firm, representing as IP transactional counsel a variety of emerging growth and publicly held companies primarily in Silicon Valley,Seattle and Austin, and had a particular focus in cloud services, privacy, and security, negotiating transactions with global 1000 companies, including a number of large healthcare organizations.
Prior to attending Michigan Law School and graduating Cum Laude, Todd flew as a Mission Commander in long range Navy patrol aircraft, served in combat in the first Gulf War, staying in the Navy Reserves and ending his career with the rank of Commander.
Juli Goldstein, MHS
Vice President of Government Affairs and Market Access
Juli Goldstein is the Vice President for Government Affairs and Market Access. In her role, she runs payer, advocacy and policy outreach. Juli has over 20 years of experience across the global healthcare industry.
She has held roles in the medical device and health insurance sectors, where her responsibilities have included strategic business planning for new medical technologies and creating coverage policies and benefit designs within a managed care environment. Most recently, Juli led the government affairs, channel strategy and policy functions at Medela. She is a frequent public speaker and has published in The Journal of Preventive Medicine, The American Journal of Managed Care, and the American Association of Health Plans.
Juli holds her Master’s degree in Health Science/International Health from the Johns Hopkins University Bloomberg School of Public Health.
Young Kwon, MD, PhD
Dr. Young H. Kwon is a renowned glaucoma specialist at the University of Iowa Hospitals and Clinics, where he is Professor of Ophthalmology and Visual Sciences and holds the Clifford M. and Ruth M. Altermatt Endowed Professorship in Glaucoma.
For almost a decade, Dr. Kwon was a member of the Preferred Practice Pattern Glaucoma Panel at The American Academy of Ophthalmology, which outlines best practices for the diagnosis and treatment of glaucoma.
He has authored over 140 peer-reviewed papers and scientific book chapters, including an article in The New England Journal of Medicine (2009), and served as a Glaucoma Section Editor and Editorial Board Member of Eye, The Scientific Journal of the Royal College of Ophthalmologists (UK).
He has been recognized with many awards, including Mid-Career Clinician-Scientist Award from The American Glaucoma Society Secretariat Award and Senior Achievement Award from The American Academy of Ophthalmology and “Best Doctors in America.”
Dr. Kwon is the inventor of four patents (two of them with Dr. Abramoff) and his research has been funded through a variety of private, state, and federal organizations since 1997. He holds an MD from the Yale University School of Medicine and a PhD in Neuroscience from the Massachusetts Institute of Technology.
He completed his ophthalmology residency training at Massachusetts Eye & Ear Infirmary (a Harvard teaching hospital) and glaucoma fellowship at Yale University.
Harry Quigley, MD
Dr. Quigley was born in St. Louis and is a graduate of Harvard College and Johns Hopkins Medical School (Alpha Omega Alpha). After ophthalmic residency at the Wilmer Institute, he did a fellowship with Douglas Anderson at the Bascom Palmer Eye Institute, Miami.
He became the A. Edward Maumenee Professor of Ophthalmology in 1994, directing both the Glaucoma Center of Excellence and, until 2011, the Dana Center for Preventive Ophthalmology at Wilmer.
He was a founding member of the American Glaucoma Society, serving for 8 years as its Secretary. He was elected to 5 year terms as chief executive officer of the Association for Research in Vision and Ophthalmology (ARVO) and Editor-in-Chief of Investigative Ophthalmology and Visual Science.
He has published over 400 peer-reviewed articles, and his reports are the most cited in the ophthalmic literature over the last 30 years (Archives of Ophthalmology, 2007; H factor 118, 59,000 citations).
He has been honored with the Friedenwald Award by ARVO, the Doyne Medal by the Oxford Ophthalmological Congress, the Leslie Dana Medal by the St. Louis Society for the Blind, and by research awards from Research to Prevent Blindness, the Alcon Research Award (twice), the European Society of Ophthalmology (Prix Jules Francois), the Chicago Ophthalmological Society (best teacher), Ophthalmological Society of Scotland (Mackenzie Medal), Australian Society of Ophthalmology (Gregg Medal), Irish Ophthalmological Society (Mooney Medal), and the New York Academy of Sciences (Lewis Rudin Prize).
He is an ARVO Gold Fellow and received ARVO’s Joanne Angle Service Award from ARVO and the Life Achievement Honor Award of the American Academy of Ophthalmology. He has given 43 named lectures, including the 66th Edward Jackson Lecture (AAO).
Dr. Quigley has trained 65 glaucoma clinician–scientists who lead glaucoma centers in the U.S. and worldwide. His research has improved the early diagnosis of glaucoma and has developed instruments and techniques to identify glaucoma damage better.
His investigations found that early glaucoma damage preceded existing detection methods. He was the first to report on long-term success with laser iridotomy. His suturing technique for trabeculectomy has been widely adopted.
He has participated in pioneering studies of the epidemiology, morbidity and progression rate of glaucoma and other eye diseases in American, African, Asian, and Hispanic populations, serving as a consultant to the World Health Organization.
He conceptualized new roles for iris and choroidal volume change as risk factors in angle closure glaucoma. In the laboratory, he has demonstrated successful gene therapy to protect retinal ganglion cells from experimental glaucoma, and developed glaucoma models in monkeys, rats and mice.
Dr. Quigley is an advocate of natural gardening techniques in ecorestoration projects in Baltimore, developing Poplar Hill Park (see www.waytogarden.net). He is a Horticultural Assistant at the National Aquarium, Baltimore. His son, David, is on the University of California San Francisco faculty in Oncology and Epidemiology as a bioinformatics specialist in cancer research. His daughter, Erica, is a landscape architect, designing outdoor play spaces. He loves being asked about his 2 grand-daughters.
James Folk, MD
Dr. Folk is the Judith (Gardner) and Donald H. Beisner Professor of Vitreoretinal Diseases and Surgery at the University of Iowa. He has won numerous awards and is a world recognized leader in vitreoretinal disease
He has written over 200 papers, book chapters and books in his field including the American Academy of Ophthalmology’s books on the treatment of diabetic retinopathy. He has been the principal investigator of 18 National and International Clinical Trials testing new therapies for eye disease.
He is on the editorial board of the journal RETINA, and has served on the AAO Preferred Practice Panel for Vitreoretinal Diseases. He is a past President of The Macula Society.
Senator William H. Frist, MD
Senator William Frist, MD, is a nationally recognized heart and lung transplant surgeon, former U.S. Senate Majority Leader, founding partner of Frist Cressey Ventures and Special Partner of the health service investment firm Cressey & Company.
As a U.S. Senator representing Tennessee from 1994 -2006 (the first practicing physician elected to the Senate since 1928), Dr. Frist was elected Majority Leader of the Senate, having served fewer total years in Congress than any person chosen to lead that body in history. His leadership was instrumental in the passage of the 2003 Medicare Modernization Act that established Medicare Advantage and the historic PEPFAR legislation that has provided life-saving treatment globally to 20 million people.
Senator Frist graduated from Princeton University and Harvard Medical School, and completed surgical training at Massachusetts General Hospital and Stanford.
As a leading authority on virtual healthcare delivery, Senator Frist speaks nationally on health reform, government policy, global health, and education reform. He is Co-Chair of the Health Project at the Bipartisan Policy Center. His board service includes the Robert Wood Johnson Foundation, The Nature Conservancy, and three publicly-traded companies: Select Medical, Teladoc Health, and Smile Direct Club.
Dr. Frist is married and has three sons and lives on a farm in Franklin, Tennessee.
Ambassador Howard Leach
Howard H. Leach is a business executive and private investor. He serves as president of Leach Capital, LLC, Palm Beach, Florida. Howard served as the United States Ambassador to France from 2001 to 2005. He was a member of the Board of Regents of the University of California from 1990 to 2001 and served as chairman of that board from 1993 to 1995.
Howard has served as director of various companies, including president of Foley Timber and Land Company, Perry, Florida; chairman of Hunter Fan Company, Memphis, Tennessee; Shippers Development Company, Salinas, California; Dr. Pepper Company; the FL Aerospace Corporation (successor to Midland Ross Corporation); and Hibernia Bank and as chairman of Sybron Corporation and the Union Ice Company.
Howard is active in civic activities and serves on the Boards of The Society of the Four Arts, the Palm Beach Civic Association, the Preservation Foundation of Palm Beach, The American Society of the French Legion of Honor, and the Center for Strategic and International Studies. He is also on the Board of the American Hospital of Paris Foundation. He was a member of the California State Board of Agriculture and the U.S. Chamber of Commerce Committee on Agriculture.
Howard has been active in Republican politics for many years. He served as finance chairman of the Republican National Committee from 1995 to 1997. Howard is a graduate of Yale University and attended Stanford Graduate School of Business. He served as an officer in the U.S. Air Force from 1953 through 1955.
Howard and his wife, Gretchen, reside in Palm Beach, Florida.
Drew Oetting is co-founder and Managing Partner for 8VC, a Silicon Valley-based venture capital firm which manages over $3.5B. Drew focuses on software, healthcare delivery, and bio-IT investments.
Drew serves on the Competitiveness Council of Cerberus. He is a board member of Thorn, a non-profit which builds technology to prevent child trafficking and LivingOnOne, an impact film making studio.
He is a board trustee for the Claremont McKenna Center for Innovation and Entrepreneurship, as well as at the Robert Day Financial Economics Institute
Drew grew up in Iowa City, Iowa and received a BS in math and economics from Claremont McKenna College.
Lisa Tseng, MD
Since joining UnitedHealth Group in 2009, Dr. Lisa Tseng has built and led businesses that have improved consumer experience and health outcomes while improving affordability. She currently serves as Executive Vice President, focusing on strategic partnerships and scaling innovative health solutions.
Dr. Tseng led the implementation of utilization management, quality improvement, provider enrollment and credentialing, claims service center, provider training, electronic visit verification, and program integrity services to support a $3.5 billion state program. She served as the CEO of Optum Complex Care Management, which is the market leader in delivering person-centric care to people with complex medical, behavioral, and long-term care needs in 36 states.
Dr. Tseng led the development and operation of a post-acute transition program in more than 47 markets and 30 states providing transitional care to members discharged from hospitals and nursing facilities. She designed the end-to-end clinical model, process, and system that enabled clinicians to be by the member’s side within 24 hours and with a full view of the member’s medical and pharmaceutical history.
Dr. Tseng led the development of urgent care clinics that provide on-demand access to high quality care at low prices in several states, including same-day labs and imaging, occupational health, and wellness programs.She led the advancement of Specialty Pharmacy Clinical Management Programs, which have improved member and provider experience, improved medication adherence, reduced hospitalizations and ER visits, and reduced total cost of care. Her team built an innovative, direct-to-consumer hearing aid business that reduced the cost of hearing aids by more than 70%, making hearing healthcare more accessible for 48 million Americans with hearing loss. The business received the Business Intelligence Group Award for Consumer Friendly Company of the Year.
Dr. Tseng served as Chief of Staff for UnitedHealthcare’s Public and Senior Markets Group including Medicare and Medicaid. She also served as Vice President of Strategy and Business Development at Fidelity Investments, Vice President of Corporate Integration Strategy for AARP Services, and management consultant at Oliver Wyman. Dr. Tseng holds a Bachelor of Science degree in Physiological Science and minor in Neuroscience from UCLA and Medical Degree from the UCLA School of Medicine. She served on the National Leadership Team of the American Medical Student Association and was the National President of the Asian Pacific American Medical Student Association. Dr. Tseng has also served on the board of several community health clinics. She was the business chair for the Minneapolis Walk4Hearing.
She has been recognized by Modern Healthcare’s Up & Comers Award, Women’s Health Leadership TRUST, Minneapolis St. Paul Business Journal Women in Business Award, Women Worth Watching, Business Journal Diversity in Business Award, and UnitedHealth Group Innovation Award. Dr. Tseng was also profiled in the Entrepreneur magazine, Managed Care magazine, and Diversity Journal.